Onglyza safety concerns prompt Dear Healthcare Professional letters
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and AstraZeneca have sent Dear Healthcare Professional letters in the EU and US alerting doctors to post-marketing reports of serious hypersensitivity reactions to their antidiabetic Onglyza (saxagliptin).